



## Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

October 31, 2024

ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured presentation in the Late Breaker/Featured Science track and three poster presentations have been accepted for the AHA Scientific Sessions 2024 in Chicago, IL, November 16-18, 2024.

### **Featured Science**

#### ***Bempedoic Acid and Limb Outcomes in Statin-Intolerant Patients with Peripheral Artery Disease: New Insights from the CLEAR Outcomes Trial***

Featured Science: Vascular Outcomes in the Spotlight

November 18, 2024, 8 - 9:15 a.m. CST

Presenter: Marc P. Bonaca, MD, MPH, FAHA, FACC

### **Poster Presentations**

#### ***Liver Steatosis and Liver Fibrosis Predict Major Adverse Cardiovascular Events in the CLEAR Outcomes Trial***

Poster Presentation

CVD Science Smorgasbord II

Zone 3, Science & Technology Hall

November 16, 2024, 10:30 - 11:30 a.m. CST

Presenter: Diederick (Rick) Grobbee, MD, PhD, FESC

#### ***Statin Intolerance due to Muscle Symptoms Affects Management of Patients: Insights from the CLEAR Outcomes Trial***

Moderated Digital Poster Presentation 15

Lipids and Management – A Deep Dive

Zone 3, Science & Technology Hall

November 16, 2024, 11:50 - 11:55 a.m. CST

Presenter: Ulrich Laufs, MD, PhD

#### ***Effectiveness of Lipid-lowering Therapy with Bempedoic Acid plus Ezetimibe in a Real-world Cohort***

Moderated Digital Poster Presentation 1

Clinical and Translational Studies of Lipoproteins and Lipids in Vascular Diseases

Zone 1, Science & Technology Hall

November 16, 2024, 1:40 - 1:45 p.m. CST

Presenter: Evelyn Sarnes, PharmD

### **Esperion Therapeutics**

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life's work. For more information, visit [esperion.com](https://esperion.com) and [esperionscience.com](https://esperionscience.com) and follow us on X at [twitter.com/EsperionInc](https://twitter.com/EsperionInc).

### **Esperion Contact Information:**

Investors:

Alina Venezia

[investorrelations@esperion.com](mailto:investorrelations@esperion.com)

(734) 887-3903

Media:

Tiffany Aldrich

[corporateteam@esperion.com](mailto:corporateteam@esperion.com)

(616) 443-8438